Carl Dahlberg
Pulmonary Disease · Columbus, TXNPI 1376596130
Payments from drug & device makers
Across 119 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$348
- Mylan Specialty L.p.$207
- AbbVie$197
- Inspire Medical Systems, Inc.$183
- Regeneron Healthcare Solutions, Inc.$173
- Insmed, Inc.$172
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,356100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $348 |
| Mylan Specialty L.p. | 8 | $207 |
| AbbVie | 12 | $197 |
| Inspire Medical Systems, Inc. | 10 | $183 |
| Regeneron Healthcare Solutions, Inc. | 7 | $173 |
| Insmed, Inc. | 8 | $172 |
| AstraZeneca(2 entities) | 8 | $152 |
| Sanofi | 6 | $138 |
| Electromed, Inc. | 11 | $116 |
| Viatris Specialty LLC | 4 | $96 |
| Pfizer | 4 | $84 |
| Harmony Biosciences LLC | 4 | $79 |
| Dexcom, Inc. | 3 | $69 |
| Amgen | 3 | $66 |
| Grifols USA, LLC | 2 | $48 |
| United Therapeutics Corporation | 2 | $44 |
| Bayer | 2 | $41 |
| Abiomed | 1 | $36 |
| Merck | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $15 |
How this compares
$2,356 in reported general payments places this provider in the 45th percentile of 904 pulmonary disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 12 | $319,186 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 259 | $247,836 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $185,177 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 108 | $102,724 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $61,378 |
| XolairOmalizumab | 13 | $59,113 |
| Spiriva RespimatTiotropium Bromide | 47 | $34,617 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 50 | $31,222 |
| EliquisApixaban | 45 | $29,857 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $27,268 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $12,080 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $10,957 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 52 | $10,415 |
| Advair DiskusFluticasone Propion/Salmeterol | 25 | $8,990 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 311 | $7,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $348 | $321,294366 claims |
| Grifols USA, LLCProlastin C | $48 | $185,17711 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $152 | $129,992177 claims |
| PfizerEliquis | $84 | $29,85745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Columbus
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.